Publications & Resources

For Plasma Donation, Donor Health is the Top Priority

European Commission’s proposal for an EU Regulation on standards of quality and safety for substances of human origin intended for human application (SoHO Regulation)

PPTA Position Paper (2022)

Stockpiling: EU needs effective measures to facilitate access to lifesaving medicines made of human plasma (PDMPs)

PPTA Position Paper (2022)

Compensating plasma donors (2022)

Differentiating plasma from blood (2022)

Safety of donors (2022)

PPTA The importance of the EU-US MRA for patient access to plasma-derived medicinal products (PDMPs)

PPTA Position Paper (2022)

PPTA Member and EU Manufacturing Sites

This map lists commercial manufacturing sites globally, with a focus on the EU, and non-commercial facilities in the EU. This map illustrates the strong manufacturing footprint of our sector. In the European Union, there are 17 commercial and three non-profit facilities.

PPTA Core Policy Report

“Plasma donation: New thinking to serve Europe’s patients”

New thinking & approaches to plasma donation to benefit Europe’s patients

PPTA EU Blood Directive Position Paper

“Together toward a broader European plasma donation ecosystem”

English Czech (Čeština) Deutsch Español Français Magyar Polski

https://www.itsinusalltosavealife.org/

Key Economic and Value Considerations for Plasma-derived Medicinal Products (PDMPs) in Europe

Kluszczynski, Rohr & Ernst (2020). Vintura White Paper.

Statement from the European Commission: Coronavirus

European Commission strengthens support for treatment through convalescent plasma.

Coronavirus disease 2019 (COVID-19) and supply of substances of human origin in the EU/EEA

Plasma for the manufacturing of medicinal products is considered to be an essential Substance of Human Origin

Commission staff working document on the implementation of the principle of voluntary and unpaid donation

For human blood and blood components as foreseen in Directive 2002/98/EC on setting standards of quality and safety for the collection, testing, processing, storage, and distribution of human blood and blood components and amending Directive 2001/83/EC.

Council of Europe DH BIO Guide of the Principle of Prohibition of Financial Gain

PPTA Europe needs to collect more plasma

PPTA Position Paper (2019)

Reported by countries in the EC 2nd Report on Voluntary and Unpaid Donation of Blood and Blood Components

Key Economic and Value Considerations in the U.S. Market for Plasma Protein Therapies

Manning & Grabowski (2018). Bates White Economic Consulting.